

09/992832

(FILE 'HOME' ENTERED AT 22:11:50 ON 17 OCT 2004)

FILE 'REGISTRY' ENTERED AT 22:12:01 ON 17 OCT 2004

L1 1 S METHYLPHENIDATE/CN
L2 0 S DESTROAMPHETAMINE/CN
L3 1 S DEXTROAMPHETAMINE/CN
L4 1 S L1

FILE 'USPATFULL, EMBASE, CAPLUS, BIOSIS' ENTERED AT 22:16:33 ON 17 OCT 2004

L5 10514 S L1
L6 17030 S L3
L7 25402 S L6 OR L5
L8 2294 S L7 AND PLACEBO
L9 45 S L7 (P) PLACEBO
L10 1 S L7(W) PLACEBO
L11 45 DUP REM L9 (0 DUPLICATES REMOVED)

blessing

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1983:155179 CAPLUS
 DOCUMENT NUMBER: 98:155179
 TITLE: Psychological effects of dopamine β -hydroxylase inhibition: a failure to replicate
 AUTHOR(S): Hartmann, Ernest; Oldfield, Molly; Adelman, Susan; Edelberg, Rob
 CORPORATE SOURCE: Sch. Med., Tufts Univ., Boston, MA, USA
 SOURCE: Psychopharmacology (Berlin, Germany) (1983), 79(4), 352-6
 CODEN: PSCHDL; ISSN: 0033-3158
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB In a previous investigation of whether reduced dopamine- β -hydroxylase (DBH) [9013-38-1] might play a role in schizophrenia, the effects of DBH inhibition for a few hours were studied in normal subjects. This initial study showed pos. effects, i.e., unusual subjective psychol. reports confirmed by psychiatric rating scales, in subjects given the DBH inhibitor fusaric acid [536-69-6]. The present study attempted to replicate these findings using a more detailed battery of tests and an addnl. control situation. Each subject underwent the following 4 treatment conditions at 1-wk intervals: fusaric acid plus L-dopa [59-92-7]; L-dopa alone; d-amphetamine [51-64-9]; **placebo**. The present results did not confirm those of the first study.

AB In a previous investigation of whether reduced dopamine- β -hydroxylase (DBH) [9013-38-1] might play a role in schizophrenia, the effects of DBH inhibition for a few hours were studied in normal subjects. This initial study showed pos. effects, i.e., unusual subjective psychol. reports confirmed by psychiatric rating scales, in subjects given the DBH inhibitor fusaric acid [536-69-6]. The present study attempted to replicate these findings using a more detailed battery of tests and an addnl. control situation. Each subject underwent the following 4 treatment conditions at 1-wk intervals: fusaric acid plus L-dopa [59-92-7]; L-dopa alone; d-amphetamine [51-64-9]; **placebo**. The present results did not confirm those of the first study.